One recent study showed that reduced MIF expression was observed in bevacizumab-resistant glioma cells, which in turn was associated with increased M2-like TAM recruitment and the promotion of tumor progression and further resistance to anti-angiogenic treatment38. This evidence concerns the gene MIF and glioma.